BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//https://www.rotaryclubofnorthsydneysunrise.org.au///NONSGML kigkonsult.se iCalcreator 2.10.15//
METHOD:PUBLISH
BEGIN:VEVENT
UID:20200301T160032UTC-4521rrVp5n@https://www.rotaryclubofnorthsydneysunris
 e.org.au/
DTSTAMP:20200301T160032Z
DESCRIPTION:Melanoma is a type of skin cancer affecting both adults and chi
 ldren\, and is the third most common cancer in Australia. Immunotherapy is
  a type of biological therapy that stimulates the body’s immune system to 
 fight cancer cells.  Melanoma patients who have received Immunotherapy hav
 e an overall survival rate of 70%. Although the majority of melanoma patie
 nts responded to immunotherapy\, nearly 50% of patients developed drug res
 istance or experienced toxicities during treatment. \nAs melanoma tumours 
 are diverse and composed of distinct genetic and phenotypic features\, the
  cells within the tumours are heterogenous. This heterogeneity of cells in
  cancer can be a major clinical problem because heterogeneity reduces the 
 efficacy of drug resulting in failed treatment. Our recent work highlighte
 d not only the specific gene markers in cell populations that responded to
  specific immunotherapy drugs\, but also the heterogeneity of cellular gen
 e expression among the non-responding patients who failed treatment. \nNew
  single-cell sequencing analysis identified distinct response patterns tha
 t are associated with longer progression-free survival and greater tumour 
 shrinkage in immunotherapy. Also\, the genetic expression and phenotypic p
 rofiles will facilitate rationally designed treatment strategies.\nCamelia
  will explain this leading-edge work and its significance in treating Mela
 noma and other cancers.\n \nCamelia is Postdoctoral Scientist at the Centr
 al Clinical School\, Melanoma Institute Australia.   Her research goal is 
 to reshape the molecular determinants of treatment response\, resistance\,
  toxicity and survival in order to improve outcomes in patients. Her curre
 nt work involved Phase I\, II and III clinical trials in advanced metastat
 ic melanoma\, particularly focus on identifying molecular biomarker that c
 orrelates with response and resistance to cancer immunotherapy. 
DTSTART:20200406T210000Z
DTEND:20200406T223000Z
LOCATION:Piato Restaurant (123 Blues Point Road\, McMahons Point NSW 2060\,
  Australia)
SUMMARY:Immunotherapy
END:VEVENT
END:VCALENDAR